[Brachytherapy for prostate cancer: old concept, new techniques]

Area of Science:

• Oncology
• Radiotherapy
• Medical Physics

Context:

• Prostate brachytherapy, proposed a century ago, has recently advanced due to technological innovations.
• Endorectal echography, improved seed/micro-source development, and 3D dosimetry enable precise real-time implantation.
• Increasing prostate cancer incidence and detection of localized forms drive treatment modality exploration.

Purpose:

• To evaluate the efficacy and outcomes of prostate brachytherapy for localized prostate cancer.
• To compare brachytherapy (permanent and high-dose rate) with traditional treatments like surgery and conformal radiotherapy.
• To assess the evolving role and future indications of brachytherapy in prostate cancer management.

Summary:

• Permanent prostate brachytherapy (Iodine-125, Palladium-103) shows 10-15 year results comparable to surgery for select localized cases (PSA < 10, Gleason < 7).
• This technique demonstrates lower rates of incontinence and impotence compared to conventional surgery, though temporary urinary toxicity is noted.
• High-dose rate (HDR) brachytherapy, combined with conformal radiotherapy, is indicated for advanced or intermediate-risk prostate cancer and as an alternative for low-risk cases, especially in cost-sensitive regions.

Impact:

• Brachytherapy is becoming increasingly indicated due to an aging population, improved detection of localized disease, and patient preference for reduced toxicity.
• Technological advancements and anticipated cost reductions position brachytherapy as a competitive and viable prostate cancer treatment option.
• The technique's potential for comparable efficacy with improved quality of life outcomes highlights its growing significance in oncological practice.